{"id":"allogeneic-stem-cell-transplant","safety":{"commonSideEffects":[{"rate":"30–50%","effect":"Graft-versus-host disease (GVHD)"},{"rate":"40–60%","effect":"Infection"},{"rate":"40–80%","effect":"Mucositis"},{"rate":"5–15%","effect":"Hepatic veno-occlusive disease"},{"rate":"5–10%","effect":"Graft failure or rejection"},{"rate":"5–10%","effect":"Secondary malignancy"}]},"_chembl":{"chemblId":"CHEMBL5315108","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The transplanted allogeneic stem cells engraft in the recipient's bone marrow and differentiate into functional blood and immune cells, reconstituting the hematopoietic system. This approach is used to treat hematologic malignancies, severe aplastic anemia, and certain genetic disorders. The donor immune cells may also provide a graft-versus-tumor (GVT) effect that helps eliminate residual malignant cells.","oneSentence":"Allogeneic stem cell transplant replaces a patient's diseased or damaged bone marrow with healthy stem cells from a donor to restore normal hematopoietic and immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:22.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Chronic myeloid leukemia (CML)"},{"name":"Myelodysplastic syndrome (MDS)"},{"name":"Severe aplastic anemia"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT00128960","phase":"","title":"Quality of Life in Patients Who Have Undergone Stem Cell Transplant","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2005-08-11","conditions":"Long Term Psychological Affects on HSCT","enrollment":173},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT05909202","phase":"NA","title":"A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2024-06-05","conditions":"Neoplasm, Caregivers","enrollment":218},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT06905834","phase":"PHASE2","title":"Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2026-05","conditions":"Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD)","enrollment":30},{"nctId":"NCT05071222","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-19","conditions":"Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency","enrollment":7},{"nctId":"NCT01087294","phase":"PHASE1","title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-04","conditions":"Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins","enrollment":85},{"nctId":"NCT02669251","phase":"PHASE1, PHASE2","title":"Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-28","conditions":"Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome","enrollment":14},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT05531786","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-06","conditions":"Graft vs Host Disease","enrollment":50},{"nctId":"NCT01303146","phase":"PHASE2","title":"Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Metachromatic Leukodystrophy","enrollment":1},{"nctId":"NCT03286530","phase":"PHASE2","title":"Ruxolitinib + Allogeneic Stem Cell Transplantation in AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation","enrollment":64},{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT00001529","phase":"","title":"Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1996-03-18","conditions":"Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis","enrollment":500},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT07250087","phase":"PHASE1","title":"Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-01-21","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT06209190","phase":"NA","title":"Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-09-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":14},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT07483385","phase":"NA","title":"Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"The General Hospital of Western Theater Command","startDate":"2026-01-13","conditions":"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders","enrollment":45},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT05919511","phase":"","title":"Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-08-01","conditions":"cGVHD","enrollment":1500},{"nctId":"NCT00092235","phase":"","title":"Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-26","conditions":"Chronic Graft vs. Host Disease","enrollment":650},{"nctId":"NCT00576979","phase":"PHASE1, PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":"Leukemia","enrollment":51},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT07006506","phase":"PHASE2","title":"A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-21","conditions":"Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy","enrollment":46},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT00106925","phase":"","title":"Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-04-22","conditions":"Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection","enrollment":1000},{"nctId":"NCT07488728","phase":"NA","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2025-10-01","conditions":"EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir","enrollment":80},{"nctId":"NCT07214688","phase":"PHASE2","title":"Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-01-06","conditions":"Allogeneic Stem Cell Transplant Recipient","enrollment":209},{"nctId":"NCT06093867","phase":"","title":"Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-04-08","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":40},{"nctId":"NCT07463651","phase":"PHASE3","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-05-01","conditions":"Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT)","enrollment":594},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT02257853","phase":"PHASE2","title":"Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2015-01-05","conditions":"Stress, Psychological, Caregivers","enrollment":53},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06440135","phase":"PHASE1","title":"Ziftomenib Maintenance Post Allo-HCT","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-06-11","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation","enrollment":22},{"nctId":"NCT03180216","phase":"PHASE1","title":"T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2017-02-15","conditions":"Viral Infections, Bone Marrow Transplant Infection","enrollment":32},{"nctId":"NCT01315132","phase":"PHASE2","title":"A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2008-04-10","conditions":"Hematological Malignancies, Leukemia, Lymphoma","enrollment":47},{"nctId":"NCT02789228","phase":"PHASE1","title":"Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2016-10-12","conditions":"Solid Tumors","enrollment":28},{"nctId":"NCT04044365","phase":"","title":"Pediatric cGVHD Symptom Scale","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-02","conditions":"Graft vs Host Disease","enrollment":420},{"nctId":"NCT05796570","phase":"PHASE2","title":"A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies","status":"RECRUITING","sponsor":"Franziska Wachter","startDate":"2023-04-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies","enrollment":37},{"nctId":"NCT06279676","phase":"","title":"Improvement of Women's Health After Allogeneic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2024-08-27","conditions":"GVHD, Chronic","enrollment":100},{"nctId":"NCT03441958","phase":"PHASE1, PHASE2","title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-03-07","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT03494569","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-07-06","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia","enrollment":36},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT07476014","phase":"EARLY_PHASE1","title":"Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-28","conditions":"Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":18},{"nctId":"NCT04692181","phase":"PHASE1, PHASE2","title":"SYN-004 Safety and Tolerability in Allo-HCT Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theriva Biologics, Inc.","startDate":"2021-02-15","conditions":"Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics","enrollment":36},{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT04579523","phase":"PHASE1","title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07235501","phase":"","title":"Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-06-01","conditions":"Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":75},{"nctId":"NCT07387367","phase":"PHASE3","title":"A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT","status":"RECRUITING","sponsor":"SymBio Pharmaceuticals","startDate":"2026-02-15","conditions":"Adenovirus Infections","enrollment":180},{"nctId":"NCT07470996","phase":"","title":"T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-10-01","conditions":"Peripheral T Cell Lymphoma","enrollment":58},{"nctId":"NCT03728335","phase":"PHASE2","title":"Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-07-11","conditions":"Acute Myeloid Leukemia","enrollment":35},{"nctId":"NCT04829136","phase":"NA","title":"Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-06-22","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":30},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT06198517","phase":"NA","title":"Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT","status":"RECRUITING","sponsor":"Yi Zhang","startDate":"2024-03-21","conditions":"Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis","enrollment":266},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT03980769","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-05","conditions":"Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","enrollment":40},{"nctId":"NCT04230356","phase":"PHASE2","title":"Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-01-27","conditions":"Allogeneic Stell Cell Transplant, Viral Infection","enrollment":180},{"nctId":"NCT05834244","phase":"PHASE1","title":"A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-26","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT06625190","phase":"PHASE1, PHASE2","title":"Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-02-11","conditions":"Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma","enrollment":27},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT05236062","phase":"NA","title":"Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-04-14","conditions":"Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease","enrollment":36},{"nctId":"NCT07464483","phase":"NA","title":"Multi-omic Characterization of Pediatric and Adult Patients Undergoing Hematopoietic Stem Cell Transplantation and Advanced Cell Therapies","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-11-21","conditions":"Bone Marrow Replaced Via Transplant","enrollment":260},{"nctId":"NCT07381205","phase":"","title":"Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)","status":"NOT_YET_RECRUITING","sponsor":"Manuel Ricardo Espinoza-Gutarra","startDate":"2026-07-01","conditions":"Transplant Associated Microangiopathy TAM, Transplant Complication","enrollment":85},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT07140770","phase":"","title":"Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-02","conditions":"Physical Activity, Sleep, Allogenic Hematopoietic Cell Transplant","enrollment":66},{"nctId":"NCT06707493","phase":"PHASE2","title":"Ivosidenib as Post-HSCT Maintenance for AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-16","conditions":"IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)","enrollment":75},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT06856226","phase":"","title":"Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-04","conditions":"Leukemia, Lymphoma, Hematologic Malignancy","enrollment":88},{"nctId":"NCT01366612","phase":"PHASE3","title":"PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-16","conditions":"Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia","enrollment":53},{"nctId":"NCT06326008","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-15","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse","enrollment":48},{"nctId":"NCT06649201","phase":"","title":"Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-12-19","conditions":"Graft Vs Host Disease, Vulvovaginal Signs and Symptoms","enrollment":40},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":53},{"nctId":"NCT04128501","phase":"PHASE2","title":"Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-05","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT03602599","phase":"","title":"Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls","status":"RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2018-11-15","conditions":"Graft Versus Host Disease","enrollment":500},{"nctId":"NCT07225985","phase":"PHASE1, PHASE2","title":"Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-05-01","conditions":"Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma","enrollment":50},{"nctId":"NCT07451236","phase":"PHASE1, PHASE2","title":"CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA","status":"NOT_YET_RECRUITING","sponsor":"Chang Yingjun","startDate":"2026-03-18","conditions":"Transplantation Candidates With Hematological Diseases","enrollment":18},{"nctId":"NCT07456189","phase":"NA","title":"The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-14","conditions":"HSCT, Hematologic Cancer","enrollment":20},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT07455500","phase":"NA","title":"Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2026-05","conditions":"Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT06575296","phase":"PHASE1","title":"Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-12-06","conditions":"Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia","enrollment":27},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT03652441","phase":"PHASE2","title":"Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2019-11-13","conditions":"Classical Hodgkin Lymphoma","enrollment":14},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03541889","phase":"PHASE1","title":"REVEAL Biomarkers of Engraftment After Alternative Donor HSCT","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2021-02-05","conditions":"Primary Graft Failure","enrollment":56},{"nctId":"NCT06543381","phase":"PHASE1","title":"Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-17","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT06498973","phase":"PHASE1","title":"Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-28","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":43},{"nctId":"NCT01520623","phase":"NA","title":"Complement and Graft-versus-host Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-04","conditions":"Allografted With Myeloablative Conditioning","enrollment":70},{"nctId":"NCT06874283","phase":"","title":"Ocular Complications From Cancer Therapy - Patient Registry and Biobank","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-05-13","conditions":"Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease","enrollment":150},{"nctId":"NCT04914338","phase":"NA","title":"A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-06-03","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":40},{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1719,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allogeneic Hematopoietic Stem Cell Transplantation"],"phase":"phase_3","status":"active","brandName":"allogeneic stem cell transplant","genericName":"allogeneic stem cell transplant","companyName":"University of Wuerzburg","companyId":"university-of-wuerzburg","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allogeneic stem cell transplant involves the transplantation of multipotent hematopoietic stem cells from a donor into a recipient, typically to replicate and produce normal blood cells. This procedure is used to treat various conditions, including leukemia, acute myeloid leukemia in remission, and neuroblastoma, among others.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}